TAK-020

• Description:

  TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.

• UNSPSC:

  12352005

• Target:

  Btk

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/tak-020.html

• Purity:

  99.93

• Solubility:

  DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles:

  O=C1NNC(C2=CC3=C(C(O[C@@H]4CN(C(C=C)=O)CC4)=N2)C=CC=C3)=N1

• Molecular Formula:

  C18H17N5O3

• Molecular Weight:

  351.36

• References & Citations:

  [1]Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S) -5- (1- ((1-Acryloylpyrrolidin-3-yl) oxy) isoquinolin-3-yl) -2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64 (17) :12893-12902.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [1627603-21-7]